EGFR and non-small cell lung carcinoma: Furthermore, a randomized phase 3 study compared osimertinib versus chemotherapy for EGFR T790M positive advanced NSCLC and determined that LVEF occurred in 5% of osimertinib-treated patients at a dose of 80 mg/day, with a median time of 5.5 months to outset of decreased LVEF (Mok et al., 2017).